Article
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Oct 2007
Chen Yen-Ching, Kraft Peter, Bretsky Philip, Ketkar Shamika, Hunter David J, Albanes Demetrius, Altshuler David, Andriole Gerald, Berg Christine D, Boeing Heiner, Burtt Noel, Bueno-de-Mesquita Bas, Cann Howard, Canzian Federico, Chanock Stephen, Dunning Alison, Feigelson Heather S, Freedman Matthew, Gaziano J Michael, Giovannucci Edward, Sánchez Maria-Jose, Haiman Christopher A, Hallmans Göran, Hayes Richard B, Henderson Brian E, Hirschhorn Joel, Kaaks Rudolf, Key Timothy J, Kolonel Laurence N, LeMarchand Loic, Ma Jing, Overvad Kim, Palli Domenico, Pharaoh Paul, Pike Malcolm, Riboli Eliot, Rodriguez Carmen, Setiawan V Wendy, Stampfer Meir, Stram Daniel O, Thomas Gilles, Thun Michael J, Travis Ruth C, Virtamo Jarmo, Trichopoulou Antonia, Wacholder Sholom, Weinstein Stephanie J
Abstract excerpt
BACKGROUND: Estrogen receptor beta (ESR2) may play a role in modulating prostate carcinogenesis through the regulation of genes related to cell proliferation and apoptosis. METHODS: We conducted nested case-control studies in the Breast and Prostate Cancer Cohort Consortium (BPC3) that pooled 8,323 prostate cancer cases and 9,412 controls from seven cohorts. Whites were the predominant ethnic group. We...
Read the complete abstract on PubMed